KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to $41.1 million.

  • CRISPR Therapeutics AG's Accumulated Expenses rose 78.34% to $84.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.2 million, marking a year-over-year increase of 78.34%. This contributed to the annual value of $41.1 million for FY2024, which is 9.40% down from last year.
  • According to the latest figures from FY2024, CRISPR Therapeutics AG's Accumulated Expenses is $41.1 million, which was down 9.40% from $45.3 million recorded in FY2023.
  • CRISPR Therapeutics AG's Accumulated Expenses' 5-year high stood at $91.0 million during FY2021, with a 5-year trough of $41.1 million in FY2024.
  • Its 3-year average for Accumulated Expenses is $54.7 million, with a median of $45.3 million in 2023.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Accumulated Expenses surged by 78.20% in 2020, and later tumbled by 41.64% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Accumulated Expenses (Yearly) stood at $53.8 million in 2020, then surged by 69.21% to $91.0 million in 2021, then fell by 14.64% to $77.7 million in 2022, then crashed by 41.64% to $45.3 million in 2023, then decreased by 9.40% to $41.1 million in 2024.